Enhanced Group Inc.

What they do

The company operates two business lines: the Enhanced Games, a multi-sport event built around medically supervised performance enhancement, and Live Enhanced, a direct-to-consumer subscription platform offering physician-guided protocols, telehealth access and personalized supplementation. The inaugural Enhanced Games were held in May 2026 at Resorts World Las Vegas and featured swimming, track and weightlifting competitions. Live Enhanced was introduced in February 2026 and commenced full commercial operations, including fulfillment, in the United States in May 2026. The company describes its model as asset-light and partnership-driven, relying on third-party telehealth, production and distribution partners while retaining brand, technology, customer relationships and data.

Revenue drivers

• Enhanced Games sponsorship — Sponsorship revenue recognized in connection with the inaugural Enhanced Games drove the $17.7 million reported for the second quarter of 2026; the company said it secured approximately $32 million of sponsorship contract value for the first-year event with recognition occurring over several quarters.
• Media rights — The company signed an exclusive media rights agreement with Roku to deliver the Games to 100 million North American households; no revenue figure for this agreement was disclosed.
• Live Enhanced subscriptions and products — A direct-to-consumer subscription platform launched with an athlete-branded protocol stack, 11 Rx therapies and two proprietary supplement products, introduced February 2026 and fully operational in May 2026; no separate revenue contribution was reported.
• Licensed consumer products and branded content — The company states it intends to monetize the Enhanced Games through branded content and licensed consumer products in addition to sponsorships and media rights; no figures were provided.

Recent performance

For the three months ended June 30, 2026, the company reported revenue of $17.7 million, primarily sponsorship revenue recognized in connection with the inaugural Enhanced Games, and a net loss of $61.9 million. The loss reflected costs of staging the inaugural Games, the IRB clinical trial, the de-SPAC merger completion, higher general and administrative costs from operating as a public company, and the launch of the direct-to-consumer platform. Adjusted EBITDA loss was $42.7 million, and cash and cash equivalents were $19.6 million as of June 30, 2026. Annual net losses widened to $26.7 million in 2025 from $4.7 million in 2024, with operating cash flow of negative $24.4 million in 2025. Total assets were $45.4 million and total liabilities $42.3 million at June 30, 2026, leaving shareholder equity of $3.1 million.

Strategy

Management describes the inaugural Games as a deliberate, costly investment to build brand recognition and serve as a customer acquisition engine for the performance medicine platform. In July 2026 the company expanded beyond one tentpole event per year with the Enhanced Breakers Series, which it says operates at a fraction of the cost of a full Games event and keeps athletes, audiences and sponsors engaged year-round. The company also said it expects to expand Live Enhanced with additional peptide-based offerings, currently offering Sermorelin and stating it may add Tesamorelin, Glutathione and Oxytocin if permitted by law and regulation. It states it intends to monetize the Games through media rights, sponsorships, branded content and licensed consumer products, and to run a partnership-driven model that retains control of brand, technology, customer relationships and data.

Risks

• History of losses and cash consumption — The company has incurred net losses since inception, including $78.4 million for the six months ended June 30, 2026, negative operating cash flow of $24.4 million in 2025, and $3.1 million of shareholder equity at June 30, 2026.
• Event-driven revenue concentration — Second quarter 2026 revenue of $17.7 million was primarily sponsorship tied to the inaugural Enhanced Games, while quarterly revenue was effectively zero in the prior-year periods.
• Regulatory dependence of peptide offerings — The company states that availability, timing and scope of additional peptide offerings remain subject to regulatory requirements and that the peptide expansion is not assured.
• Middle East operational exposure — Athlete training and medical preparation and the IRB-approved clinical research study were conducted in the U.A.E., and the company identifies geopolitical instability and armed conflict in the Middle East as a risk that could disrupt those activities.

Outlook

Management said the second quarter reflected an intentional decision to invest heavily in the inaugural Enhanced Games and that the company expects to incur operating losses for the foreseeable future as it invests in infrastructure, product development, marketing and talent. It points to the newly launched Enhanced Breakers Series and planned participatory events as a lower-cost way to sustain attention between Games, and to anticipated regulatory developments in the peptide space as a potential tailwind for Live Enhanced. The company has not provided specific revenue or earnings guidance.